


PredicineATLAS

600-Gene Liquid Biopsy Panel For TMB

cfDNA panel for comprehensive variant profiling and accurate TMB calculation

- Complete detection of SNVs, Indels, CNVs, and re-arrangements in major cancer pathways
- Accurate estimation of TMB
- 2.4 Mb broad genome coverage
- Covers genes of interest across drug development pipeline from targeted therapies to immunology therapies

Proprietary cfDNA variant detection workflow



Methods and Reporting

- Uses a proprietary hybrid capture-based next-generation sequencing methodology combined with in-house proprietary computational algorithms that enable accurate and sensitive detection of cancer variants
- Utilizes proprietary workflow to accurately identify unique cfDNA fragments from blood
- Test results are provided in an interpretive report with clinically relevant genomic findings listed

PERFORMANCE SPECIFICATIONS			
	Allele Frequency/Copy Number	Positive Predictive Value (PPV)	Sensitivity
Single Nucleotide Variations	≥0.5%	100%	> 99.9%
	0.25% - 0.5%	99.5%	95.6%
	0.1% - 0.25%	99%	70.0%
Copy Number Amplifications	≥2.3 copies	100%	100%
Indels	≥0.5%	100%	100%
	0.25% - 0.5%	100%	94.1%
	0.1% - 0.25%	100%	72.0%
Re-arrangements	≥0.5% AF	100%	100%
	0.25% - 0.5%	100%	85.0%
	0.1% - 0.25%	100%	70.0%
Reproducibility (average concordance between replicates)	98.1% inter-batch precision 96.5% intra-batch precision		
Specimen Type and Requirement	Liquid biopsy	4ml plasma 10ml whole blood 40ml urine	
	Tissue biopsy	10 FFPE slides or frozen tissues	
Turnaround Time	10 days		
Regions Analyzed	600 genes		
Panel Size	2.4 Mb		
Sequencing and Bioinformatics	Illumina NGS		
Assay Sensitivity	0.25% report down to 0.1%		
Target Sequence Coverage	>20,000X for biofluid		
	>2,000X for tissue		